Skip to main content
Fig. 3 | Hereditas

Fig. 3

From: Identification of MMP1 as a potential gene conferring erlotinib resistance in non-small cell lung cancer based on bioinformatics analyses

Fig. 3

MMP1 is identified as a potential gene conferring erlotinib resistance in NSCLC. a Venn diagram of significantly upregulated DEGs in GSE80344 and GSE19188. b The expressions of MMP1were verified through datasets GSE38121 (P = 2.06E-8, Log2 FC = 6.52), GSE69181 (P = 2.25E-7, Log2 FC = 1.61) and GSE80344 (P = 5.67E-3, Log2 FC = 2.39) in erlotinib resistant NSCLC cells. The expressions of MMP1were verified through datasets c GSE7670 (P = 8.01E-10, Fold Change = 21.925) and d GSE10072 (P = 1.12E-15, Fold Change = 7.277) in NSCLC tissues and normal lung tissues. e Box-plot revealing that the expression levels of MMP1 is significantly different between NSCLC (LUAD and LUSC) tissues and normal lung tissues by the GEPIA2 online tool (|log2 (Fold change) | > 2 and P < 0.01). f and g Survival analysis of MMP1 in NSCLC patients was obtained from KM plotter (GSE50081, HR = 1.87 (1.06–3.31), log-rank P = 0.028; GSE31210, HR = 2.42 (1.19–4.95), log-rank P = 0.012). LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma

Back to article page